Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Expansion Outlook: What Revenue Opportunities Are Ahead?
The investigational new drug contract development and manufacturing organization (cdmo) market has experienced strong expansion in recent years. It is anticipated to grow from $5.91 billion in 2025 to $6.33 billion in 2026, at a compound annual growth rate (CAGR) of 7.1%. The growth observed in the past can be attributed to factors such as the limited availability of CDMOs for investigational drugs, an increasing demand for small molecule synthesis, a reliance on conventional manufacturing services, growing clinical trial volumes, and the early adoption of regulatory support services.
The investigational new drug contract development and manufacturing organization (cdmo) market size is anticipated to experience substantial expansion in the upcoming years. Its valuation is projected to reach $8.17 billion by 2030, reflecting a compound annual growth rate (CAGR) of 6.6%. This growth during the forecast period can be attributed to the broadening of gene and cell therapy manufacturing capabilities, a heightened demand for monoclonal antibodies and recombinant proteins, increased investment in advanced formulation technologies, the implementation of scalable manufacturing platforms, and a rise in global biotechnology research collaborations. Significant trends expected in this period include an escalating demand for early-stage drug development services, the expansion of clinical trial material supply services, a stronger emphasis on regulatory compliance and quality standards, the development of biologics and advanced therapies, and the adoption of custom manufacturing solutions for both small and large molecules.
Get A Free Sample Report With In-Depth Market Insights:
Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Growth Factors Behind Sustained Expansion
The expansion of clinical trials is projected to fuel the advancement of the investigational new drug contract development and manufacturing organization (CDMO) market in the coming period. These trials are meticulously structured research endeavors that involve human volunteers to assess the safety and efficacy of medical treatments, procedures, or interventions within controlled environments. This increase in clinical trials primarily stems from the escalating need for novel therapies, with the rising prevalence of chronic and intricate diseases compelling pharmaceutical and biotechnology firms to create and evaluate new remedies. Investigational new drug CDMOs facilitate clinical trials by optimizing the production and formulation of drugs ready for testing, thereby guaranteeing a prompt and compliant provision of investigational products for every stage of a study. As an illustration, in December 2024, data from the Association of the British Pharmaceutical Industry, a UK-based pharmaceutical trade body, indicated that the overall number of industry-backed clinical trials commenced in the United Kingdom rose from 411 in 2022 to 426 in 2023. Concurrently, Phase III trial starts saw an increase of 16.5 percent during this identical timeframe, moving from 182 to 212. Consequently, the expanding volume of clinical trials is stimulating the development of the investigational new drug contract development and manufacturing organization (CDMO) market.
Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Segment Analysis: What Are The Core Market Categories?
The investigational new drug contract development and manufacturing organization (cdmo) market covered in this report is segmented –
1) By Product: Small Molecules, Large Molecules
2) By Formulation Type: Solid Formulations, Liquid Formulations, Injectable Formulations
3) By Service Type: Clinical Trial Material Supply, Regulatory Support Services, Manufacturing Services
4) By End-User: Biotechnology Companies, Academic And Research Institutes, Other End-Users
Subsegments:
1) By Small Molecules: Synthetic Small Molecules, Semi-synthetic Small Molecules, Peptide-based Small Molecules, Oligonucleotides
2) By Large Molecules: Monoclonal Antibodies (mAbs), Recombinant Proteins, Vaccines, Cell Therapy Products, Gene Therapy Products, RNA-based Therapeutics
Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Industry Trends Fueling Future Revenue Growth
Leading companies in the investigational new drug contract development and manufacturing organization (CDMO) market are concentrating on strategic alliances to bolster their development capabilities and accelerate entry into clinical trials. Such strategic partnerships denote formal arrangements between two or more entities that collaborate to achieve common objectives, utilizing each other’s strengths, resources, or specialized knowledge for mutual benefits while maintaining their distinct autonomy. For example, in August 2023, Sartorius AG, a Germany-based life science company, collaborated with Repligen Corporation, a US-based life sciences company, to unveil an integrated system combining the BIOSTAT STR and XCell ATF technologies for upstream process intensification. This joint effort seeks to optimize biopharmaceutical production by enhancing both efficiency and scalability. The undertaking underscores Sartorius’ ongoing innovation in bioprocessing solutions, reaffirming its dedication to the advancement of the biomanufacturing industry.
Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Top Companies Driving Competitive Growth
Major companies operating in the investigational new drug contract development and manufacturing organization (cdmo) market are Thermo Fisher Scientific Inc., Fresenius Kabi AG, Lonza Group Ltd., Catalent Inc., Samsung Biologics Co. Ltd., Fareva SA, Recipharm AB, PCI Pharma Services, Vetter Pharma, Delpharm, Kindeva Drug Delivery LP, Ajinomoto Bio-Pharma Services, Cenexi SAS, Grand River Aseptic Manufacturing Inc., INCOG BioPharma Services, Aurigene Pharmaceutical Services, Jubilant HollisterStier LLC, Symbiosis Pharmaceutical Services Ltd., Afton Scientific Corp., Amaran Biotech Inc.
View The Full Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Report:
Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Regional Outlook: Where Is Opportunity Concentrated?
North America was the largest region in the investigational new drug contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the investigational new drug contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model